Teclistamab impairs humoral immunity in heavily pretreated MM patients: importance of immunoglobulin supplementation
Description
Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in heavily pretreated multiple myeloma (MM) patients, but are associated with a high rate of infections. BCMA is also expressed
